REGeRNA

Start date: 01 September 2022

End date: 31 August 2027

REGeRNA

Share

The main aim of the REGeRNA project is to develop a synthetic messenger RNA capable of reinducing cardiomyocyte proliferation in patients suffering from heart failure.
Heart failure (HF) is a major health problem worldwide because of the high number of patients and the related costs.
Current treatments are not consistently efficacious and fail to address the major underlying cause of Heart failure: the massive loss of cardiomyocytes in damaged regions.
REGeRNA has been designed to address this issue by leveraging advances in synthetic mRNAs and their lipid nanoparticle (LNP)-based carriers to generate a construct able to reactivate mechanisms mediating cardiomyocyte proliferation in development but which are shut-down shortly after birth. REGeRNA is organised in 6 work packages that follow a roadmap towards endogenous heart repair.



Scientific coordinator of the project: Philippe Menasché

See also

Collaborative projects

High-quality support for a research excellence.

EXPOSIGNALZ

Horizon Europe

The link between environmental pollutants and Alzheimer’s disease

Human populations are exposed to harmful chemical pollutants found in the environment. Some of them may ...

PROACT EU-Response

Horizon Europe

Building Europe’s pandemic preparedness network

The COVID-19 pandemic exposed vulnerabilities in Europe’s ability to respond swiftly to emerging health crises. Without ...

SERENA

Horizon Europe

Effective support for maltreated children

Child maltreatment remains a widespread and underreported issue across Europe with devastating impacts on victims and society. ...

HPV-FASTER-Implement

Horizon Europe

The European HPV-FASTER-Implement project aims to strengthen the prevention of cervical cancer among vulnerable populations. Although vaccination against human papillomavirus (HPV) and screening ...

SOLVE

Horizon Europe

Decoding immunity to address SARS-CoV-2 challenges.

Despite the swift development of SARS-CoV-2 vaccines, the pandemic persists due to emerging variants and waning ...

IMPROVE PRETERM

Horizon Europe

Taking care of very preterm infants.

Each year, over 50 000 infants are born very preterm (before 32 weeks of gestation) in Europe and face lifelong challenges such as ...

INVENTS

Horizon Europe

The evaluation of new medicines for rare diseases is challenging for several reasons, among which are the small patient sample sizes, heterogeneity of patients and diseases and heterogeneity in ...

HT-ADVANCE

Horizon Europe

HT-ADVANCE we aim to revolutionise personalised management of arterial hypertension (HT) by using multi-omics (MOMICS) stratification biomarkers as companion diagnostics for the prescription of ...

MPX-RESPONSE

Horizon Europe

The aims of the MPX-RESPONSE project were to enhance understanding of mpox (Monkeypox), evaluate potential treatments, and bolster Europe's preparedness for emerging infectious disease ...

ARTIDe

Horizon Europe

ARTiDe aims to develop a new antigen-specific immunotherapy for type 1 diabetes, via genetic engineering, using patients' regulatory T lymphocytes (Treg) to express an autoreactive T lymphocyte ...

MITI2

Horizon Europe

Inflammatory bowel disease (IBD) refers to a group of chronic conditions that cause inflammation in the digestive tract. IBD requires long-term management and treatment, which includes medication, ...

OBELISK

Horizon Europe

The Obelisk project consists of developing tools for predicting obesity during the first 1,000 days of life and testing innovative prevention programs, particularly among adolescents, in several ...

BE READY

Horizon Europe

Pandemic preparedness for future disease outbreaks

Experience with pandemics has highlighted the need for planning ahead and being prepared.
With this in mind, the ...

ISIDORe

Horizon Europe

The ISIDORe project assembles the largest and most diverse research and service-providing instrument to study infectious diseases in Europe, with expertise from structural biology to clinical ...

CARE-IN-HEALTH

Horizon Europe

Cardiovascular disease prevention through an immunological blueprint
Epidemiological evidence suggests an association between chronic inflammation and risk for cardiovascular disease (CVD). ...

INTERCEPT-T2D

Horizon Europe

Inflammatory-based interceptive medicine in type 2 diabetes
Individuals with type 2 diabetes (T2D) do not use insulin efficiently and, therefore, their glucose levels rise. ...

HERVCOV

Horizon Europe

The HERVCOV project aims to analyze the role of human endogenous retroviruses (HERVs), known for their high pro-inflammatory potential, in the immunopathogenesis of COVID-19 and its long-term ...

RITA-MI 2

H2020

RITA-MI 2 will conduct a phase 2b randomised double-blind placebo-controlled CT to assess the impact of B cell depletion with the CD20 mAb rituximab on left ventricular dysfunction and cardiac ...

CBIG-SCREEN

H2020

CBIG-SCREEN aims to tackle inequality in cervical cancer screening (CCS) continuum. Though CCS programmes drastically reduce cervical cancer mortality, they remain largely inaccessible and ...

EJP-RD

H2020

The European Joint Program on Rare Diseases brings over 130 institutions from 35 countries 27 EU Member States (Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, ...

REMEDIA

H2020

The overall objective of the REMEDIA project is to determine how and to what extent the exposome affects the severity and morbidity of Chronic Obstructive Pulmonary Disease (COPD) and Cystic ...

CARDIATEAM

IMI

Diabetic patients are 2.5 times more likely to develop heart failure than people without diabetes. In many patients, the diabetes causes a type of heart dysfunction called cardiomyopathy, which is ...

COSY

RHU

The aim of our project is to transform the outcome and the medical care of patients with overgrowth syndromes (OS)

...

EU-TRAIN

H2020

"End stage renal diseases affect more than 3,900,000 patients worldwide with approximately 6% growth rate in 2016.
Kidney transplantation is currently the best therapeutic option with around ...

CARE

IMI

The CARE consortium is a coalition of 37 academic institutions, pharmaceutical companies and non-profit research organizations whose main objectives are the development of therapeutics (i) to ...

TheraLymph

H2020

Lymphedema is a disabling condition of localised accumulation of fluid in a tissue caused by a compromised lymphatic system. It is an incurable disease that affects millions of people worldwide and...

IP-CURE-B

H2020

To develop novel curative concepts for chronic hepatitis B (CHB). The project aims to improve the cure rate of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune...

CCHFVaccine

H2020

The general aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) ...

R-LINK

H2020

The main objective of this study is to identify the eligibility criteria for treatment with lithium in bipolar I disorders (BDI) in terms of response, safety and tolerability. R-LiNK proposes a ...

PREVAC-UP

The project PREVAC-UP is built around the PREVAC consortium.

Its two primary objectives are to determine (i) the long-term immunogenicity and safety and (ii) durability of humoral and ...

PREMSTEM

H2020

PREMSTEM aims to validate umbilical cord derived human mesenchymal stem cells as a regenerative therapy for encephalopathy of prematurity to improve the quality of life for preterm infants and ...

OBERON

H2020

The OBERON project will build an integrated approach for testing and assessment (IATA) to detect endocrine disruptors-related metabolic disorders by developing, improving and validating a battery ...

miniNO

H2020

The miniNO project will conduct out pioneering research on the connection between alterations in minipuberty and infantile nitric oxide (NO) signaling in the brain, and comorbidities that appear ...

MAD-CoV 2

IMI

The overall aim of MAD-CoV 2 project is to develop and deliver a treatment for COVID-19 patients, which will significantly increase our capacity to handle the current outbreak of SARS-CoV-2. In ...

JPcofuND2

H2020

With the objective of promoting research aimed at changing the trajectory of these debilitating diseases, JPco-fuND 2 launched in January 2019, a joint transnational call supported by 27 countries ...

FAIR

H2020

The project aims to assess an adjunct to antibiotic therapy as an emerging concept to overcome antimicrobial resistance in pneumonia. The research focuses on the unique immunomodulator flagellin ...

EU-RESPONSE

H2020

The overall objective of this 5-year project is to build a multinational, adaptive European COVID-19 and emerging infectious diseases trial network, based on existing initiatives, experience and ...